News | Webinars | Publications | Conferences | Upcoming Events |
-
November 6, 2019
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP) -
November 4, 2019
PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer -
October 30, 2019
PsychoGenics Announces Milestones Associated with Sunovion’s Advancing Pipeline -
September 27, 2019
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia -
May 10, 2019
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia